Published in Nat Genet on May 20, 2012
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
Organoid cultures derived from patients with advanced prostate cancer. Cell (2014) 3.12
Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell (2014) 3.05
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Transcriptional regulation and its misregulation in disease. Cell (2013) 2.92
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol (2014) 2.75
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell (2016) 2.26
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02
The Mediator complex: a central integrator of transcription. Nat Rev Mol Cell Biol (2015) 1.97
The promise of whole-exome sequencing in medical genetics. J Hum Genet (2013) 1.95
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2013) 1.85
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep (2014) 1.68
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A (2013) 1.66
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 1.56
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
Cell-fate determination by ubiquitin-dependent regulation of translation. Nature (2015) 1.55
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun (2015) 1.49
Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet (2015) 1.47
Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (2014) 1.45
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun (2016) 1.44
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res (2016) 1.39
Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A (2014) 1.38
Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.37
The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37
Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics (2014) 1.33
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep (2014) 1.29
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun (2014) 1.27
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A (2013) 1.26
Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer (2013) 1.26
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res (2013) 1.26
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell (2015) 1.25
Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer (2013) 1.25
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res (2012) 1.24
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer (2012) 1.24
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (2014) 1.23
bHLH-PAS proteins in cancer. Nat Rev Cancer (2013) 1.23
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med (2017) 1.21
Mutations in MED12 cause X-linked Ohdo syndrome. Am J Hum Genet (2013) 1.20
Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res (2015) 1.18
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med (2017) 1.17
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res (2013) 1.16
Advancing precision medicine for prostate cancer through genomics. J Clin Oncol (2013) 1.16
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med (2017) 1.16
The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug Discov Today (2014) 1.16
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A (2012) 1.16
Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res (2014) 1.15
Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep (2014) 1.14
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol (2013) 1.12
The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl (2013) 1.11
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors. Mol Cancer Res (2015) 1.10
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford) (2014) 1.10
New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res (2012) 1.09
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
MED12 related disorders. Am J Med Genet A (2013) 1.07
Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet (2015) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Inactivating CUX1 mutations promote tumorigenesis. Nat Genet (2013) 1.06
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget (2014) 1.05
Global cancer statistics. CA Cancer J Clin (2011) 185.92
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
GenePattern 2.0. Nat Genet (2006) 29.07
miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
The UCSC Genome Browser database: update 2011. Nucleic Acids Res (2010) 16.24
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res (2010) 11.32
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature (1993) 7.56
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol (2011) 5.11
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
ORegAnno: an open-access community-driven resource for regulatory annotation. Nucleic Acids Res (2007) 3.80
Laser-capture microdissection. Nat Protoc (2006) 3.80
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell (2007) 2.88
Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell (2009) 2.84
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics (1997) 2.65
Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer (2010) 2.61
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res (2011) 1.89
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene (2011) 1.69
A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. J Biol Chem (2002) 1.66
Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. Development (2010) 1.65
BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene (2006) 1.48
Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest (2010) 1.48
Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.40
SOX9 interacts with a component of the human thyroid hormone receptor-associated protein complex. Nucleic Acids Res (2002) 1.38
Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett (1997) 1.35
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res (2003) 1.31
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
The generic genome browser: a building block for a model organism system database. Genome Res (2002) 42.64
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (2009) 29.83
Sequencing and comparison of yeast species to identify genes and regulatory elements. Nature (2003) 29.16
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Transcriptional regulatory code of a eukaryotic genome. Nature (2004) 27.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
High-quality draft assemblies of mammalian genomes from massively parallel sequence data. Proc Natl Acad Sci U S A (2010) 22.97
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A (2009) 20.66
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
ALLPATHS: de novo assembly of whole-genome shotgun microreads. Genome Res (2008) 20.61
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet (2008) 19.55
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96